Aspect Biosystems and Novo Nordisk A/S announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. "The collaboration will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing," the companies stated. Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide license to use Aspect’s bioprinting technology to develop up to four products for the treatment of diabetes and/or obesity. Aspect will receive initial payments of $75M, including an upfront payment, research funding and an investment in the form of a convertible note. Aspect is also eligible to receive up to $650M in future development, regulatory, commercial and sales milestone payments per product, as well as tiered royalties on future product sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk price target raised to DKK 1,152 from DKK 1,081 at Guggenheim
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports
- Aeterna Zentaris says sales of Macrilen to be temporarily discontinued in U.S.
- Viking Therapeutics price target raised to $31 from $20 at BTIG
- Novo Nordisk reports PIONEER PLUS trial achieved primary endpoint